AbCellera Biologics (ABCL) Change in Accured Expenses (2024 - 2026)

AbCellera Biologics has reported Change in Accured Expenses for 3 years, with the latest figure at -$9.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 175.92% year-over-year to -$9.4 million; the trailing twelve-month figure through Mar 2026 stood at -$2.5 million (down 120.98% YoY), and the FY2025 full-year result was $3.5 million, down 67.49% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$9.4 million, down from $5.7 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $6.6 million in Q4 2024, with the low at -$9.4 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $520666.7 across 3 years, with a median of $4.1 million in 2024.
• The largest YoY upside for Change in Accured Expenses was 30.11% in 2025 against a maximum downside of 183.13% in 2025.
• AbCellera Biologics' Change in Accured Expenses stood at $6.6 million in 2024, then slipped by 13.21% to $5.7 million in 2025, then plunged by 263.78% to -$9.4 million in 2026.
• The last three Change in Accured Expenses figures came in at -$9.4 million (Q1 2026), $5.7 million (Q4 2025), and $5.1 million (Q3 2025), per Business Quant data.